<DOC>
	<DOC>NCT01287260</DOC>
	<brief_summary>This is a clinical study evaluating the superiority in efficacy and assess safety and tolerability of BAYA1040_Nifedipine 80 mg/day (40 mg twice daily) compared with BAYA1040_Nifedipine 40 mg/day (40 mg once daily) in patients with essential hypertension who are not at target blood pressure by BAYA1040_Nifedipine 40 mg once daily treatment.</brief_summary>
	<brief_title>High Dose BAYA1040_Nifedipine: a Dose-comparative Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>20 years or older Japanese male or female Outpatient with essential hypertension Patients whose sitting diastolic blood pressure (DBP) is 90 mmHg or more despite more than 4 weeks of treatment with antihypertensive drug Sitting diastolic blood pressure (DBP) is 110 mmHg or more or sitting systolic blood pressure (SBP) is 180 mmHg or more Patients with secondary hypertension or hypertensive emergency</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>BAYA1040_Nifedipine</keyword>
	<keyword>Nifedipine</keyword>
	<keyword>Essential hypertension</keyword>
	<keyword>Japanese Patients</keyword>
	<keyword>Phase III</keyword>
	<keyword>13176</keyword>
</DOC>